BHUBANESWAR: In a defining breakthrough for the global fight against thalassaemia, the US Food and Drug Administration (FDA) ...

In a defining breakthrough for the global fight against thalassaemia, the US Food and Drug Administration (FDA) has approved ...

Study reveals that reversible chemical modifications can inhibit pyruvate kinase and affect its variants differently, ...

Agios Pharmaceuticals has reported full-year 2025 results, with revenue rising to US$54.03 million from US$36.50 million a year earlier, while swinging from net income of US$673.73 million to a net ...

Agios Pharmaceuticals AGIO reported a loss of $1.85 per share in the fourth quarter of 2025, narrower than the Zacks Consensus Estimate of a loss of $1.97. In the year-ago quarter, the company had ...

PYRUKYND® (mitapivat) worldwide net revenues of $20.0 million in fourth quarter and $54.0 million for full yearAQVESME™ (mitapivat) for thalassemia now available in U.S. following FDA approvalCompany ...

PYRUKYND (mitapivat) worldwide net revenues of $20.0 million in fourth quarter and $54.0 million for full yearAQVESME (mitapivat) for thalassemia now available in U.S. following FDA approvalCompany wi ...

A clinical trial testing the oral therapy tebapivat for sickle cell disease is fully enrolled, with early results expected later this year.

Medically reviewed by Suzanne Fisher, RD Key Takeaways If you're entering ketosis, drink plenty of fluids and make sure ...